Literature DB >> 8537044

Absence of ras gene mutations in early gastric carcinomas.

M E Craanen1, P Blok, B Top, L Boerrigter, W Dekker, G J Offerhaus, G N Tytgat, S Rodenhuis.   

Abstract

The aims of this study were to assess the prevalence and type of activating point mutations at codons 12, 13, and 61 of the Ki-, Ha-, and N-ras genes in a series of early gastric carcinomas in white patients and to correlate these ras gene mutations, if any, with the histological type (Lauren classification), the type of growth pattern, and with the Helicobacter pylori status. Haematoxylin and eosin and Giemsa stained sections from 45 formalin fixed, paraffin wax embedded early gastric carcinomas were used to assess the Lauren type, the type of growth pattern, and the antral H pylori status. DNA was extracted according to standard procedures. Mutations at codon 12 of the Ki-ras gene were examined with a polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) method and dot blot hybridisation with allele-specific 32P-labelled oligodeoxynucleotide (ASO) probes. All other ras genes were analysed with specific PCR amplification and dot blot hybridisation with ASO probes. Mutations were detected by overnight autoradiography at -70 degrees C. Some 20 intestinal-type and 25 diffuse-type early gastric carcinomas were seen. According to growth pattern, there were 24 small mucosal type early gastric carcinomas, five superficial spreading type early gastric carcinomas, and 16 penetrating type early gastric carcinomas (four penetrating A type, 12 penetrating B type). H pylori was found in the antral mucosa of 28 early gastric carcinomas (62%). Activating ras gene mutations were not found. It was discovered that activating point mutations at codons 12, 13, and 61 of the Ki-, Ha-, and N-ras genes do not play a part in the development of early gastric carcinomas in white subjects, irrespective of Lauren type. Moreover, differences in biological behaviour between early carcinomas with different types of growth pattern are not related to these ras gene mutations. Finally, H pylori positive and H pylori negative gastric carcinomas cannot be discriminated on the basis of ras gene mutational analysis.

Entities:  

Mesh:

Year:  1995        PMID: 8537044      PMCID: PMC1382935          DOI: 10.1136/gut.37.6.758

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  46 in total

1.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

2.  The ras oncogene. A structure and some function.

Authors:  I S Sigal
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

3.  Glycine to aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers.

Authors:  Y Nagata; M Abe; K Kobayashi; K Yoshida; T Ishibashi; T Naoe; E Nakayama; H Shiku
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

4.  Frequent overexpression, but not activation by point mutation, of ras genes in primary human gastric cancers.

Authors:  K Fujita; N Ohuchi; T Yao; M Okumura; Y Fukushima; Y Kanakura; Y Kitamura; J Fujita
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

5.  Preparation of anti-ras Mr 21,000 protein monoclonal antibodies and immunohistochemical analyses on expression of ras genes in human stomach and thyroid cancers.

Authors:  K Yoshida; K Hamatani; H Koide; H Ikeda; N Nakamura; M Akiyama; H Tsuchiyama; E Nakayama; H Shiku
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

6.  Analysis of ras gene expression in stomach cancer by anti-ras p21 monoclonal antibodies.

Authors:  K Yoshida; K Hamatani; H Koide; Y Abe; H Ikeda; H Tsuchiyama; E Nakayama; H Shiku
Journal:  Cancer Detect Prev       Date:  1988

7.  Expression of ras oncogene p21 protein in early gastric carcinoma and adjacent gastric epithelia.

Authors:  B Czerniak; F Herz; W Gorczyca; L G Koss
Journal:  Cancer       Date:  1989-10-01       Impact factor: 6.860

8.  Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer.

Authors:  W Jiang; S M Kahn; J G Guillem; S H Lu; I B Weinstein
Journal:  Oncogene       Date:  1989-07       Impact factor: 9.867

Review 9.  The ras gene family and human carcinogenesis.

Authors:  J L Bos
Journal:  Mutat Res       Date:  1988-05       Impact factor: 2.433

10.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

Authors:  C Almoguera; D Shibata; K Forrester; J Martin; N Arnheim; M Perucho
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

View more
  4 in total

1.  Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer.

Authors:  Hong-Mei Nan; Young-Jin Song; Hyo-Yung Yun; Joo-Seung Park; Heon Kim
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

2.  Expressional profiles of transcription factors in the progression of Helicobacter pylori-associated gastric carcinoma based on protein/DNA array analysis.

Authors:  Ting-Zi Hu; Li-Hua Huang; Can-Xia Xu; Xiao-Ming Liu; Yu Wang; Jing Xiao; Li Zhou; Ling Luo; Xiao-Xia Jiang
Journal:  Med Oncol       Date:  2015-11-12       Impact factor: 3.064

3.  Analysis of p53, K-ras gene mutation & Helicobacter pylori infection in patients with gastric cancer & peptic ulcer disease at a tertiary care hospital in north India.

Authors:  Ashish Saxena; Sanket Kumar Shukla; Kashi Nath Prasad; Uday Chand Ghoshal
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

4.  Analysis of KRAS gene mutation associated with Helicobacter pylori infection in patients with gastric cancer.

Authors:  Raheleh Jabini; Seyed Ahmad Eghbali; Hossein Ayatollahi; Maryam Sheikhi; Mohammadreza Farzanehfar
Journal:  Iran J Basic Med Sci       Date:  2019-05       Impact factor: 2.699

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.